ISSN:
1432-0584
Keywords:
Amifostine
;
Myelodysplastic syndrome
;
Refractory anemia
;
Tumor necrosis factor alpha
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
2 /day three times per week followed by a 2-week interval. Since tumor necrosis factor (TNF)α is a main suppressive cytokine for hematopoiesis in RA patients, serum samples for analyzing endogenous levels of TNFα were collected prior to the study and after four treatment cycles. In three patients (21%), reduced transfusion requirement with prolongation of the transfusion interval from 4 weeks to 8 weeks (two patients) and 4 weeks to 6 weeks was seen. An increase in ANC from 400/μl to 2600/μl and 200/μl to 3400/μl was observed in two patients. Platelets increased from 129,000/μl to 277,000/μl in an additional patient. In one patient, disease progression from RA to RAEB was observed. Serum TNFα levels were increased in MDS patients compared with normal controls (18.8 pg/ml vs 9.1 pg/ml), and there was no change during the treatment with amifostine (17.5 pg/ml). In conclusion, treatment with amifostine as a single agent was of limited benefit in patients with RA. The serum TNFα levels were unchanged during treatment with amifostine in RA patients.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/s002770050589
Permalink
